Life Sciences Future50 report

Published

October 19, 2023

Life Sciences Future50 report

OMass leverages novel biochemistry techniques, native mass spectrometry and custom chemistry to develop small molecule therapeutics against well-validated but intractable or inadequately drugged targets, focusing on immunological and rare diseases.

Page 59

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...